Consistent with the luciferase data, we noted a small phase advance and only a minor change in period length, although the linear growth rate of ∆ dim-5 was much slower than that of WT or ras-1 bd.
Dose-limiting myelosuppression was also noted in a phase I trial of INO-101 with TMZ (Bedikian et al, 2009).
Furthermore, encouraging early results have been noted in a phase II trial of temsirolimus plus bevacizumab in 55 patients with progressive NET.
Both the paradoxical effects on weight and lipids were also noted in a Phase 2 trial in patients with type 1 diabetes (17) and may represent a significantly different physiological action of LY2605541 compared with other insulins.
The authors noted that a phase III study is planned comparing paclitaxel 155 mg/m every 3 weeks with or without lapatinib 1500 mg/day in women with metastatic cancer (Jones et al. 2004).
To support this hypothesis, it is worthy to note a similar phase relationship between the THz amplitude and Δφ in their Φ dependences shown in Figs. 2d and 3f, respectively; they both have a onefold symmetry, and the maximum deviations of each quantity from an isotropic response occur near the same azimuth.
In our study, we noted a similar trend, where phase 2 slopes did not show any significant change pre-treatment and post-treatment (p = 0.35).
Further we note an apparent phase transition in activity; as shown in Fig. 4B after some critical value, communities tend to be longer lived.
It is interesting to note that a phase I clinical trial has been conducted by the same group for the treatment of human anaplastic thyroid carcinomas with peritumoral or intratumoral injections of the same genes (Palù, personal communication).
It is worth noting that a phase I study of BSO administered with the anticancer drug melphalan showed that continuous-infusion of BSO was relatively nontoxic and resulted in depletion of tumor glutathione [ 35, 47].
